

MedX Health Corp. Announces Third Quarter 2020 Financial Results and Grant of Stock Options

November 30, 2020 (Source) – MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR (www.sedar.com).

The Company reported revenue of \$172,889 for the three months ended September 30, 2020, compared with revenue of \$234,977 for the three months ended September 30, 2019. Revenue from SIAscopy[®] of \$74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of \$98,603 was a decrease from \$177,436 in the prior year period, but \$60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of \$1,083,772 or \$0.01 per share compared with a loss of \$577,648, or \$0.00 per share for the three months ended September 30, 2019.

The Company reported revenue of \$337,885 for the nine months ended September 30, 2020, compared with revenue of \$678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy[®] of \$127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of \$210,792 for the nine-month period was 63% lower than the \$574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of \$2,532,171 or \$0.02 per share, compared with a loss of

\$2,086,892, or \$0.01 per share for the nine months ended September 30, 2019.

“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy® units to our Brazilian distribution partner, where they will be deployed on our DermSecure® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy® on DermSecure® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”

The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of \$0.17 per share, will expire on November 25, 2025, and vest immediately.

MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.

Under the terms of the agreement, MedX will pay Venture North a monthly fee of \$6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the "Options"), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of \$0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.

Summary of Recent Announcements:

The following is a summary of recent announcements made by the Company, for which further details can be found under the Company's profile at www.sedar.com.

MedX Announces Sales Agency Agreement with Ziemer Professional Corp.

On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy[®] on Dermsecure[®] telemedicine platform across Ontario and Saskatchewan.

MedX Adds Two New Members to Board of Directors

On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is

President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada's largest providers of out-of-hospital pain management services.

MedX Expands Senior Leadership Team

On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlattous as Managing Director, Europe, Middle East & Africa ("EMEA"), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlattous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years' experience as a clinical trainer of advanced medical aesthetic equipment and technology.

MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®

On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure® and SIAscopy®. Mike Druhan, who has championed SIAscopy® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.

MedX Announces Closing of Non-Brokered Private Placement

On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at \$0.12 per unit ("Unit"), to raise up to

\$2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of \$312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of \$0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of \$24,000 were paid.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy[®] on DermSecure[®] telemedicine platform, utilizing its SIAscopy[®] technology. SIAscopy[®] is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking

statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.